IN2015KO00631A - - Google Patents

Info

Publication number
IN2015KO00631A
IN2015KO00631A IN631KO2015A IN2015KO00631A IN 2015KO00631 A IN2015KO00631 A IN 2015KO00631A IN 631KO2015 A IN631KO2015 A IN 631KO2015A IN 2015KO00631 A IN2015KO00631 A IN 2015KO00631A
Authority
IN
India
Prior art keywords
bilirubin
diagnostic device
gold nanoclusters
luminescence intensity
source
Prior art date
Application number
Inventor
Arun; Chattopadhyay
Anumita; Paul
Srestha; Basu
Amaresh Kumar; Sahoo
Original Assignee
Indian Inst Of Technology Guwahati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of IN2015KO00631A publication Critical patent/IN2015KO00631A/en
Application filed by Indian Inst Of Technology Guwahati filed Critical Indian Inst Of Technology Guwahati
Priority to US15/572,779 priority Critical patent/US11268967B2/en
Priority to IN631KO2015 priority patent/IN2015KO00631A/en
Priority to EP16802704.3A priority patent/EP3302449B1/en
Priority to PCT/IN2016/000140 priority patent/WO2016193996A1/en
Priority to CN201680032322.1A priority patent/CN107847463B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/728—Bilirubin; including biliverdin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N21/643—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" non-biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6447—Fluorescence; Phosphorescence by visual observation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6432—Quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention discloses a diagnostic device or kit for visual detection of bilirubin. Said diagnostic device or kit comprises chitosan stabilized gold nanoclusters based luminescence source, Cu2+ ions source for quenching luminescence intensity of said gold nanoclusters and recovery of quenched luminescence intensity in the presence of bilirubin. The said device enables non-invasive detection of hyperbilirubinemia by thumb impression visually or from blood serum.
IN631KO2015 2015-06-04 2016-06-02 IN2015KO00631A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US15/572,779 US11268967B2 (en) 2015-06-04 2016-06-02 Device for visual detection of bilirubin
IN631KO2015 IN2015KO00631A (en) 2015-06-04 2016-06-02
EP16802704.3A EP3302449B1 (en) 2015-06-04 2016-06-02 A device for visual detection of bilirubin
PCT/IN2016/000140 WO2016193996A1 (en) 2015-06-04 2016-06-02 A device for visual detection of bilirubin
CN201680032322.1A CN107847463B (en) 2015-06-04 2016-06-02 Device for visually detecting bilirubin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN631KO2015 IN2015KO00631A (en) 2015-06-04 2016-06-02

Publications (1)

Publication Number Publication Date
IN2015KO00631A true IN2015KO00631A (en) 2015-06-26

Family

ID=54394057

Family Applications (1)

Application Number Title Priority Date Filing Date
IN631KO2015 IN2015KO00631A (en) 2015-06-04 2016-06-02

Country Status (5)

Country Link
US (1) US11268967B2 (en)
EP (1) EP3302449B1 (en)
CN (1) CN107847463B (en)
IN (1) IN2015KO00631A (en)
WO (1) WO2016193996A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106267401B (en) * 2016-08-31 2018-12-18 武汉仝干医疗科技股份有限公司 Physics artificial liver nano-sized carbon chitin compound adsorptive reactor based on hollow fiber conduit
AU2018326175A1 (en) 2017-08-30 2020-03-05 NeoLight LLC System and methods for bilirubin analysis
CN110133302A (en) * 2019-05-09 2019-08-16 江苏师范大学 Detect the paper chip and a kind of method of quickly detection content of bilirubin of bilirubin
CN111157506B (en) * 2020-01-17 2022-10-21 天津师范大学 Method for detecting thioglycollic acid by using integrated fluorescent test paper

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992158A (en) * 1973-08-16 1976-11-16 Eastman Kodak Company Integral analytical element
JP2856757B2 (en) * 1989-03-13 1999-02-10 ユニチカ株式会社 Method for measuring total bilirubin and reagent for measurement
US6882873B2 (en) 1996-01-17 2005-04-19 Respironics, Inc. Method and system for determining bilirubin concentration
WO2002018951A2 (en) * 2000-08-29 2002-03-07 The Rockefeller University Methods employing fluorescence quenching by metal surfaces
WO2006138698A2 (en) * 2005-06-17 2006-12-28 University Of Maryland Biotechnology Institute Metal-enhanced fluorescence-based sensing methods
US20060292700A1 (en) * 2005-06-22 2006-12-28 Naishu Wang Diffused interrupted lateral flow immunoassay device and method
US20120065614A1 (en) * 2010-09-10 2012-03-15 University Of North Texas Polyionic transitional metal phosphorescent complex/polymer hybrid systems for bioimaging and sensing applications

Also Published As

Publication number Publication date
EP3302449B1 (en) 2020-04-01
CN107847463B (en) 2021-06-22
CN107847463A (en) 2018-03-27
EP3302449A4 (en) 2019-01-09
US11268967B2 (en) 2022-03-08
WO2016193996A1 (en) 2016-12-08
US20180149663A1 (en) 2018-05-31
EP3302449A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
EA201792642A1 (en) DIAGNOSTIC METHODS FOR T-CELL THERAPY
ZA201705114B (en) Cysteine protease
EA201992546A1 (en) MEANS ON THE BASIS OF ANTIBODIES TO CD33
ZA201705113B (en) Cysteine protease
MX2022008868A (en) Treatment of cancer with tg02.
WO2015111008A3 (en) Biomarkers predictive of muscle atrophy, method and use
WO2014153030A3 (en) Methods of treating cancer and preventing cancer drug resistance
MX2018011633A (en) Non-invasive diagnostic of non-alcoholic steatohepatitis.
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
MX2016012285A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression.
MX2018012493A (en) Methods for monitoring and treating cancer.
EA201691314A1 (en) THERAPEUTIC WAYS AND COMPOSITIONS
IN2015KO00631A (en)
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2015014713A (en) Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer.
MX2016001439A (en) Compositions and methods for identifying a risk of cancer in a subject.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2015168602A3 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
MX2019003569A (en) Methods for treating cancer with bavituximab based on levels of î²2-glycoprotein 1, and assays therefor.
MX2021003764A (en) Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia.
WO2017187343A3 (en) Nanoemulsions and methods for cancer therapy
WO2016133449A9 (en) Detection and treatment of malignant tumours in the cns
ZA201900669B (en) Diagnosis, treatment and prevention of neurotensin receptor-related conditions
CA2863427A1 (en) Use of pdgfr-.alpha. as diagnostic marker for papillary thyroid cancer